当前位置:首页 - 行情中心 - 安科生物(300009) - 财务分析 - 利润表

安科生物

(300009)

  

流通市值:118.16亿  总市值:162.99亿
流通股本:12.16亿   总股本:16.77亿

利润表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、营业总收入2,865,752,059.952,021,384,056.691,287,279,354.46594,174,209.84
营业收入2,865,752,059.952,021,384,056.691,287,279,354.46594,174,209.84
二、营业总成本1,930,498,177.721,257,752,219.43826,263,354.01377,413,240.03
营业成本620,344,181.63439,768,034.42286,430,556.1146,678,486.58
税金及附加24,611,653.1917,107,252.2811,437,305.185,209,625.1
销售费用831,323,114.06518,385,202.05345,361,759.01149,534,885.84
管理费用203,348,567.2131,910,705.1583,547,159.0841,645,710.6
研发费用254,679,885.17152,939,567.06100,932,188.2835,377,092.33
财务费用-3,809,223.53-2,358,541.53-1,445,613.64-1,032,560.42
其中:利息费用1,873,835.141,240,381.83776,489.16364,793.49
其中:利息收入5,894,033.334,688,003.733,008,161.111,619,883.04
加:公允价值变动收益-411,050.272,505,377.29-1,858,898.41564,009.72
加:投资收益-4,742,482.53-2,947,5951,906,115.43431,079.56
资产处置收益120,701.82-380.24-1,594.35-
资产减值损失(新)-17,483,675.33-9,215.2391,055.4936,723.02
信用减值损失(新)-20,154,961.8-6,324,908.97-3,143,782.58-1,687,340.6
其他收益31,396,697.111,618,340.735,606,580.913,804,539.51
营业利润平衡项目0000
四、营业利润923,979,111.22768,473,455.84463,615,476.94219,909,981.02
加:营业外收入65,178.5330,570.518,733.413,733.34
减:营业外支出4,114,683.87728,513.25115,858.949,841.29
利润总额平衡项目0000
五、利润总额919,929,605.88767,775,513.1463,508,351.45219,863,873.07
减:所得税费用61,340,614.31103,155,035.5761,644,850.931,012,990.63
六、净利润858,588,991.57664,620,477.53401,863,500.55188,850,882.44
持续经营净利润858,588,991.57664,620,477.53401,863,500.55188,850,882.44
归属于母公司股东的净利润847,229,426.3654,414,603.25396,356,304.7185,618,139.71
少数股东损益11,359,565.2710,205,874.285,507,195.853,232,742.73
(一)基本每股收益0.510.390.240.11
(二)稀释每股收益0.510.390.240.11
九、综合收益总额858,588,991.57664,620,477.53401,863,500.55188,850,882.44
归属于母公司股东的综合收益总额847,229,426.3654,414,603.25396,356,304.7185,618,139.71
归属于少数股东的综合收益总额11,359,565.2710,205,874.285,507,195.853,232,742.73
公告日期2024-03-282023-10-252023-08-242023-04-28
审计意见(境内)标准无保留意见
TOP↑